GP6 and ischemic stroke: The first reported function blocking anti-GPVI antibody (JAQ1) was raised against mouse GPVI.40In vivo administration of JAQ1 IgG in mice induces GPVI immunodepletion, resulting in long-term protection in a range of disease models, such as arterial thrombosis,11 ischaemic stroke,6–8 myocardial I/R injury,13 and LPS-induced lung injury10 while only moderately affecting tail bleeding time.11 Similar mechanisms of GPVI depletion also exist in humans,14,41 but persistent GPVI inhibition may not be desired in clinical settings.